Legochem Biosciences, Inc.

Abl Bio Inc.

Ligachem Biosciences Inc.

Hyeun Joung Lee

Yong Zu Kim

Ho Young Song

Ju Young Lee

Jeiwook Chae

Sung Min Kim

Kyung Eun Park

Ji Hye Oh

Yeong Soo Oh

Chul-Woong Chung

Hyo Jung Choi

Su In Lee

Hyoungrae Kim

Yun-Hee Park

Juyuel Baek

Bora Lee

Juhee Kim

Hyoung Rae Kim

Yun Hee Park

Yangsoon Lee

Byungje Sung

Donghoon Yeom

Chang Sun Lee

Dae Hyuck Kang

Kyungjin Park

Jinhyung Ahn

Jaehyun Eom

Jiseon Yoo

Daehae Song

Minji Park

Hyun Min Ryu

JinWon Jung

Ju Yuel Baek

Young-Jae Yang

Nara Han

Ji-Na You

Youngeun Hong

The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.

Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Antibody-drug conjugate comprising antibody against human ROR1 and use for the same

The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.

Growing community of inventors

Daejeon, South Korea

Hyeun Joung Lee